ENDRA Life Sciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$5.9MTTM through 30 Jun 2026
Free Cash Flow -$4.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-93.8%ROE
-74.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.64x
Net Debt-$356.5Knet cash position
Cash & Equivalents$1.7M
Quality Metrics
Altman Z-Score-18.28
Piotroski F-Score3 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2020: $0
Diluted EPS-$6.29TTMFY2025: $-8.93
Dividend
No dividend
Capital Allocation
R&D Spend$2M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| TAEUS Medical Technology | $0 | 0.0% | View detailsFocusing on commercialization of the TAEUS platform via a recurring subscription model, with a specific focus on GLP-1 and metabolic disease markets. |
| Digital Asset Treasury | $0 | View detailsSeeks to optimize capital preservation and generate non-dilutive returns through investments in decentralized finance (DeFi) assets. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.